Breaking News

Northwest Biotherapeutics Receives MHRA Approval of License for GMP Manufacturing in UK

Enables the manufacturing of DCVax-L products to get under way at the Sawston facility.

Author Image

By: Charlie Sternberg

Associate Editor

Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility.   The MHRA license approval enables the manufacturing of DCVax-L products to get under way at the Sawston facility in addition to continuing at the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters